Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common and disabling side effect of taxanes. Acetyl-L-carnitine (ALC) was unexpectedly found to increase CIPN in a randomized trial. We investigated the long-term patterns of CIPN among patients in this trial. Methods: S0715 was a randomized, double-blind, multicenter trial comparing ALC (1000 mg three times a day) with placebo for 24 weeks in women undergoing adjuvant taxane-based chemotherapy for breast cancer. CIPN was measured by the 11-item neurotoxicity (NTX) component of the FACT-Taxane scale at weeks 12, 24, 36, 52, and 104. We examined NTX scores over two years using linear mixed models for longitudinal data. Individual time points were examined using linear regression. Regression analyses included stratification factors and the baseline score as covariates. All statistical tests were twosided. Results: Four-hundred nine subjects were eligible for evaluation. Patients receiving ALC had a statistically significantly (P ¼ .01) greater reduction in NTX scores (worse CIPN) of -1.39 points (95% confidence interval [CI] ¼ -2.48 to -0.30) than the placebo group. These differences were particularly evident at weeks 24 (-1.68, 95% CI ¼ -3.02 to -0.33), 36 (-1.37, 95% CI ¼ -2.69 to -0.04), and 52 (-1.83, 95% CI ¼ -3.35 to -0.32). At 104 weeks, 39.5% on the ALC arm and 34.4% on the placebo arm reported a five-point (10%) decrease from baseline. For both treatment groups, 104-week NTX scores were statistically significantly different compared with baseline (P < .001). Conclusions: For both groups, NTX scores were reduced from baseline and remained persistently low. Twenty-four weeks of ALC therapy resulted in statistically significantly worse CIPN over two years. Understanding the mechanism of this persistent effect may inform prevention and treatment strategies. Until then, the potential efficacy and harms of commonly used supplements should be rigorously studied.
Chemotherapy-induced peripheral neuropathy (CIPN) is a common and disabling side effect of some widely used anticancer agents. To date, despite 48 randomized trials, there are no agents recommended for the prevention of CIPN (1) . There is a moderate recommendation for the treatment of painful CIPN with duloxetine. We previously reported the unexpected outcomes of a randomized double-blind placebo-controlled trial of acetyl-L-carnitine (ALC) for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy (S0715) (2) . Despite the supportive evidence from preclinical and phase II studies that ALC may be effective for both the treatment and prevention of taxane-induced symptoms of CIPN, in this large placebo-controlled trial, we found that ALC actually increased CIPN and decreased functional status relative to the placebo at 24 weeks (2) .
The symptoms of CIPN may have a waxing and waning course (3) . Up to 80% of patients treated with taxanes report some neuropathy, and about 25% to 30% report severe neuropathy up to two years following treatment (3) (4) (5) . Several crosssectional studies of patients treated with taxanes reported that persistent CIPN symptoms were associated with increased risk of falls, greater disability, and increased psychosocial distress (6, 7) . However, cross-sectional studies can be confounded by reporting bias, and most prospective studies characterizing the syndrome have been small with heterogeneous treatment regimens, nonuniform outcome measures, and/or short-term follow-up (3, 8) . The goal of this analysis was to examine long-term CIPN outcomes, out to two years, and to better characterize the clinical phenotype of CIPN.
Methods

Study Oversight
The study, registered with ClinicalTrials.gov (NCT00775645), was activated in September 2009 and closed to accrual February 2011. Patients were informed of the investigational nature of the study and signed informed consent. The study was conducted after appropriate approval by individual institutional review boards in compliance with the provisions of the Declaration of Helsinki and Good Clinical Practice guidelines.
Patient Characteristics
Women older than age 18 years with a history of stage I-III breast cancer scheduled to undergo adjuvant taxane-based chemotherapy with one of the following standard regimens were included: weekly paclitaxel 80 mg/m 2 
Study Design
A randomized, double-blind, multicenter trial comparing 3000 mg/d (six capsules) of ALC (Thorne Research, Inc., Dover, ID) with matching placebo daily for 24 weeks was conducted. Each active capsule contained 590 mg of acetyl-Lcarnitine HCL and 10 mg of cellulose. The 590 mg of acetyl-Lcarnitine HCL provides 500 mg of ALC. Each placebo capsule contained 600 mg of cellulose. Patient random assignment was stratified by planned taxane-based chemotherapy treatment and age (<60 vs 60 years). The study drug was initiated at the start of taxane chemotherapy. Following completion of the study, the capsules were retested for stability and composition.
Outcome Measures
Patients were assessed at baseline (prior to starting taxane and ALC/placebo) for peripheral neuropathy using the 11-item Neurotoxicity component of the 
Statistical Analysis
Baseline demographic factors were compared between treatment groups using chi-square tests for categorical variables and t tests for continuous variables (all two-sided tests). We examined the effect of ALC on CIPN, as measured by FACT-NTX score, over two years using linear mixed models for longitudinal data to account for correlated outcomes within patients over time. The outcome is NTX score at each time point except baseline. We specified a random intercept and slope for time and adjusted for the protocol specified stratification factors (planned taxane-based chemotherapy and age [<60 vs 60 years]) as covariates. For each model, we also adjusted for the baseline NTX score to account for any residual imbalance between intervention groups. Exploratory plots of the outcomes over time suggested a nonlinear relationship; thus, for each outcome, we modeled outcomes over time using a linear time variable and a quadratic time variable. The residual errors were determined to be normally distributed. Other patient-reported secondary outcomes (FACT-Trial Outcome Index [TOI], FACIT-Fatigue) were examined in a similar fashion. Simple linear models were used to describe potential differences in outcomes at individual assessment times.
To better characterize the clinical phenotype of CIPN, we examined the relationship between one-and two-year FACT-NTX scores and baseline factors, including age, race, ethnicity, weight, prior mastectomy, planned treatment regimen, performance status, and receipt of G-CSF (granulocyte colony-stimulating factor). Predictive factors were identified by testing the interaction of each baseline factor with treatment arm. If no interaction was evident (P > .05), then data were combined across arms, and the potential prognostic effects of the different factors were examined, adjusting for treatment arm as a covariate. Logistic regression was used to explore associations between these predictive factors and risk of a five-point decrease in FACT-NTX at year 1 and year 2. The study was designed to detect a minimally important difference of three points in the FACT-NTX score (10) . We prespecified a test of the intervention effect on the FACT-NTX over the full two years of assessments as the single primary examination, at a two-sided alpha of .05. All other tests were considered exploratory, with two-sided P values provided. All models were fit in R version 3.3.1 (R Core Team, 2013) (11) and SAS version 9.4 (SAS Institute, Inc., Cary, NC).
Results
Patient Characteristics
SWOG S0715 registered 437 patients, of whom 409 had both baseline and first follow-up outcome measures, including 208 assigned to receive ALC and 201 to placebo ( Figure 1 ). Patient characteristics were well balanced by intervention assignment for all factors, as shown in Table 1 . Patients were predominantly younger than 60 years; 9.3% percent of all included patients were black, and 4.9% were Asian. Twenty point five percent of patients had stage III disease.
Long-term Outcomes of Acetyl-L-carnitine Use
The number of patients with available FACT-NTX scores diminished over time, but was similar between arms. Missing outcome data at each time point did not exceed 5% in either treatment group and did not differ over time by group. The number of evaluable patients in the study also did not differ statistically significantly over time by arm. Mean FACT-NTX scores in both treatment groups decreased over time and were statistically significantly different at two years compared with baseline (P < .001) (Figure 2) .
We found no evidence that the trajectories over time for the FACT-NTX score differed by arm using either a quadratic (P ¼ .78) or linear interaction (P ¼ .91; data not shown). However, there was evidence that the trajectories for both arms varied over time in a quadratic fashion (P ¼ .002). Thus, the final model included both linear and quadratic variables for time, but no interaction between time and intervention arm. In this model setting, the results for the primary outcome of interest, NTX, show a statistically significant (P ¼ .01) average difference of -1.39 (95% confidence interval [CI] ¼ -2.48 to -0.30) between treatment groups, with the ALC group having lower scores (worse CIPN) on average than the placebo group (Table 2 ). These differences were particularly evident at week 24 (-1.68, 95% CI ¼ -3.02 to -0.33), week 36 (-1.37, 95% CI ¼ -2.69 to -0.04), and week 52 (-1.83, 95% CI ¼ -3.35 to -0.32). The percentage of patients with a five-point (10%) decrease from baseline at each time point is shown in Figure 3 . Figures 1 and 2,  respectively) .
We evaluated use of other medications and supplements that have been used to treat CIPN (Supplementary Figure 3 , available online). No differences by treatment at any time point were observed (data not shown). Of note, antidepressant use and omega-3 fatty acid (ie, fish oil) use increased slightly over time, and opioid use decreased over time.
Predictors of Persistent Neuropathy
Women age 60 years or older had an increased risk of worse neuropathy symptoms compared with women younger than age 60 years at year 1 (odds ratio [OR] ¼ 1.74, 95% CI ¼ 1.07 to 2.82, P ¼ .02) and year 2 (OR ¼ 1.67, 95% CI ¼ 1.02 to 2.73, P ¼ .04) ( Table 3 ). The association of weight and long-term FACT-NTX scores differed by arm at years 1 (P interaction ¼ .06) and 2 (P interaction ¼ .047). On the ALC arm, weight was associated with a 14% increased risk of worsening neuropathy per 5 kg of weight at year 1 (OR ¼ 1.14, 95% CI ¼ 1.05 to 1.24, P ¼ .002) and a 16% increased risk of worsening neuropathy per 5 kg of weight at year 2 (OR ¼ 1.16, 95% CI ¼ 1.06 to 1.26, P < .001). There was no statistically significant association between weight and decreased FACT-NTX on the placebo arm at either time point. There was no evidence that any other baseline factor was related to the risk of worsening neuropathy symptoms at either time point for either the placebo or the ALC arm.
Discussion
In this large randomized placebo-controlled trial, we showed that ALC treatment resulted in worsening of CIPN symptoms compared with placebo that persisted over two years. In addition, we showed that two years after taxane initiation, among those treated on the placebo arm, 34.4% had a persistent fivepoint decrease from baseline, and 18.0% had a persistent 10-point decrease from baseline on the FACT-NTX score. Older age was the only baseline factor that was associated with persistent symptoms in the placebo arm.
We were initially surprised to find that ALC increased CIPN during the 24-week intervention, and continue to be surprised that the difference between arms persisted throughout the twoyear period following ALC discontinuation. The reasons for this are unclear. ALC is an antioxidant, which may be contributing to a protective effect against oxidative stress (12) . Reactive oxygen species (ROS) can cause damage to DNA, which can result in tumor and normal cell death; however, they may also block treatment-generated ROS, leading to lower levels of cell damage (12, 13) . We have previously reported that patients who initiated antioxidant therapy during chemotherapy were more likely to develop CIPN six months after initiating treatment (14) . It is also possible that early development of symptoms is associated with prolonged duration of CIPN. The results suggest that more effort should be placed on ensuring safety and efficacy for over-thecounter supplements that are commonly used during cancer treatment.
Most clinical trials report adverse CIPN events during treatment, although few report the presence of persistent symptoms following treatment, and most have not used patient-reported outcomes. Therefore, the literature on long-term CIPN is very limited. Several cross-sectional studies conducted in cancer survivors report the prevalence of CIPN symptoms ranging from 30% to 80% depending on the population studied (6, 15, 16) , the measure used to assess CIPN, the timing of the measure following treatment, and the chemotherapy drug administered. However, without baseline assessment, it is difficult to determine if any of these symptoms were present prior to chemotherapy, or whether the findings may have been influenced by selection and recall bias. Several of these cross-sectional studies report a relationship between worse scores on CIPN patient-reported outcomes and decreased quality of life, increased risk of falls, and increased functional impairment (6, 7) .
Only a few prospective CIPN cohort studies that enrolled subjects prior to treatment initiation have been conducted (3,17,18) . Many of these studies suffer from small sample size, short follow-up, and treatment heterogeneity. Members of our group conducted a prospective study among 50 women with breast cancer treated with adjuvant taxane therapy. Patients were assessed at baseline, following therapy, and three, six, nine, and 12 months after completing therapy. The mean scores on the FACT-NTX decreased from 37.5 to 28.7 post-treatment (P¼.0002), and remained low 12 months after treatment. In a prior study, we found that the changes in hand/foot numbness/ discomfort were statistically significantly associated with change in vibration threshold measured with quantitative sensory testing (3). In the current study, we found similar results.
For comparison purposes, among women on the placebo arm, we found that mean FACT-NTX decreased from 41 to 37 at one year and remained at 37 at two years. Similarly, the percentage of patients with a five-point decrease from baseline was similar at years 1 and 2.
Prior studies have examined factors associated with maximum grade or symptoms of neuropathy, but few have evaluated factors associated with persistent symptoms (19) (20) (21) (22) (23) (24) (25) . Some studies suggest that race, age, and obesity may be risk factors for CIPN; however, other studies have not confirmed these findings (19) (20) (21) (22) (23) (24) (25) . In the current study, age was associated with *For the linear mixed models, the outcome is NTX score at each time point except baseline, using a random intercept and slope for time, and adjusted for planned taxane-based chemotherapy, age (<60 vs 60 persistent CIPN. Previous studies have shown an association between diabetes and the development of CIPN (26); however, patients with known diabetes were excluded from this clinical trial, so this would not have confounded the results. In the current study, baseline weight was associated with persistent CIPN among patients randomly assigned to ALC but not placebo. The reason for this interaction is unknown. A prior study found both an association between obesity and the development of CIPN and that moderate to vigorous physical activity may be associated with decreased odds of developing CIPN (14) . The current study has several unique strengths, including the size of the sample, multicenter prospective data collection, a homogeneous breast cancer population with standard taxane exposure, and long-term follow-up. However, there are also several limitations. We did not collect any objective data to define CIPN such as quantitative neurosensory tests, tests of balance, or nerve conduction tests. However, as discussed above, prior studies have shown a strong correlation between the FACT-NTX and quantitative neurosensory tests (3). The study excluded patients with baseline diabetes and where the mean Performance Status was less than 1; therefore, the results may underestimate the rate of toxicity for patients with more comorbidities. In addition, we don't know if patients developed diabetes during the study, although given the study's randomized design, there is no a priori reason to believe the development of diabetes would differ by treatment arm. Finally, the patient-reported outcome did not differentiate between sensory, motor, or autonomic neuropathy.
In summary, we found that in addition to increasing CIPN at 24 weeks, patients treated with 24 weeks of ALC had increased CIPN over the two-year follow-up period compared with placebo. We also found that CIPN persists following chemotherapy and that the worsening symptoms remained clinically meaningfully in about 30% of breast cancer patients treated with adjuvant taxane-based therapy. This is of particular interest given the increased use of taxane-based therapy over time in breast cancer patients. Currently, there is a paucity of therapies for the treatment or prevention of CIPN despite multiple prospective randomized trials (1) . The unexpected increase in CIPN from an agent presumed to reduce CIPN does emphasize the need to better understand the mechanisms of toxicities in order to better identify effective means to prevent or treat them.
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